Overview: Beta-2-Microglobulin TestIntroduction: The Beta-2-Microglobulin Test measures beta-2-microglobulin levels to monitor cancers like multiple myeloma or lymphoma, causing bone pain or fatigue. Following 2023 IMWG guidelines, it uses an immunoassay for high sensitivity, aiding in cancer screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected malignancies.
Other Names: Beta-2-Microglobulin Assay, Cancer Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Beta-2-microglobulin testing began in the 1970s with cancer research. Immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity assays improved cancer monitoring.
Purpose: Monitors multiple myeloma or lymphoma, guides treatment, and assesses disease progression in patients with bone pain or fatigue.
Test Parameters: 1. Beta 2 Microglobulin
Pretest Condition: No fasting required. Collect serum, urine, or CSF at any time. Report symptoms like bone pain or fatigue, and list medications like chemotherapy agents.
Specimen: 2-5 mL serum (SST), 5-20 mL urine (sterile container), or 1-2 mL CSF (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document cancer symptoms, history of myeloma or lymphoma, or kidney dysfunction. Include current medications, especially chemotherapy or steroids.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for chemotherapy or further testing.
Procedural Considerations: Uses an immunoassay to measure beta-2-microglobulin levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Kidney dysfunction or chemotherapy may alter levels, causing false positives. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated levels indicate advanced myeloma or lymphoma, prompting aggressive treatment. Normal levels suggest stable disease or remission.
Specialist Consultation: Consult a hematologist for result interpretation. An oncologist referral is advised for treatment planning.
Additional Supporting Tests: Serum protein electrophoresis, bone marrow biopsy, or imaging to confirm myeloma or lymphoma progression.
Test Limitations: Elevated levels may occur with kidney disease, requiring clinical correlation. False negatives may occur with early disease.
References: IMWG Myeloma Guidelines, 2023; Blood, Rajkumar SV, 2022.
